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Abstract
Background: Internal polymerase III promoters in retroviral vectors have been used extensively
to express short RNA sequences, such as ribozymes, RNA aptamers or short interfering RNA
inhibitors, in various positions and orientations. However, the stability of these promoters in the
reverse orientation has not been rigorously evaluated.
Results: A series of retroviral vectors was generated carrying the U6+1 promoter with 3 different
HIV-1 RT-specific RNA aptamers and one control aptamer, all in the reverse orientation. After
shuttle packaging, the CD4+ cell line CEMx174 was transduced with each vector, selected for
expression of GFP, and challenged with HIV-1. We did not observe inhibition of HIV-1 replication
in these transduced populations. PCR amplification of the U6+1 promoter-RNA aptamer inhibitor
cassette from transduced CEMx174 cells and RT-PCR amplification from transfected Phoenix
(amphotropic) packaging cells showed two distinct products: a full-length product of the expected
size as well as a truncated product. The sequence of the full-length PCR product was identical to
the predicted amplicon sequence. However, sequencing of the truncated product revealed a 139
bp deletion in the U6 promoter. This deletion decreased transcriptional activity of the U6
promoter. Analysis of the deleted sequences from the U6 promoter in the antisense direction
indicated consensus splice donor, splice acceptor and branch point sequences.
Conclusion: The existence of a cryptic splice site in the U6 promoter when expressed in a
retroviral vector in the reverse orientation generates deletions during packaging and may limit the
utility of this promoter for expression of small RNA inhibitors.
Background
The tRNAs, U6 small nuclear (sn) RNA and adenovirus-
virus-associated RNAs are normally expressed in cells at
high levels by RNA polymerase III. These polymerase III
promoters have been used in gene therapy applications to
express a variety of inhibitory RNAs, including RNAi,
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aptamers, ribozymes, antisense RNAs, and decoy RNAs [1-
5]. Retroviral and lentiviral vectors have been the primary
method of gene delivery to carry these inhibitor cassettes
[1,4]. Importantly, high levels of expression and inhibi-
tory activity have been demonstrated in several studies tar-
geting HIV-1 sequences with RNA polymerase III-driven
inhibitory RNAs [4,5].
While stable transduction of the transgene and vector
sequences is necessary for gene expression, several studies
reporting lack of gene function after transduction with ret-
roviral vectors have identified various mechanisms limit-
ing vector function. In several systems including our
studies, the expression cassettes have been positioned in
the vectors the in the reverse orientation to allow for the
inclusion of important regulatory sequences (poly A sig-
nals, introns, self-splicing ribozymes, etc.) so that these
signals will not affect vector genomic RNA production.
However, deletions or aberrant processing have been
identified in several of these studies due to the introduc-
tion of new cryptic regulatory sequences. For β-globin
expression, which is normally developmentally tissue-
specific regulated, generation of a retroviral vector with
the β-globin gene in the reverse orientation lead to the
identification of several RNA termination signals in the
insert [6]. Jonsson et al also found fortuitous splice sites in
the purine nucleoside phosphorylase (PNP) genomic con-
struct when inserted in a retroviral vector in the reverse
orientation [7]. Additionally, multidrug resistance 1
(MDR1) expression in transduced bone marrow and
spleen colonies resulted in both truncated and full-length
mRNA, because the cDNA was found to contain cryptic
splice donor and splice acceptor sites, even though it is
expressed in the forward direction [8]. Additionally, when
a retroviral vector contains direct repeats, deletions can
occur during reverse transcription with RNA template mis-
alignment of the polymerase growing point and the first
direct repeat [7,9]. It has been suggested that regulatory
sequences may potentially emerge in retroviral vectors
from sequences that are not naturally transcribed (i.e.
antisense sequences or the U6 promoter) [10].
Using retroviral vectors to introduce HIV-1 specific RNA
aptamers into CD4+ cell lines, we found consensus splic-
ing signals in the reverse orientation of the U6 promoter
that lead to partial deletion of the U6 promoter after ret-
roviral-mediated gene transfer. The splicing deletion lead
to reduced promoter activity, and low expression of the
aptamer in transduced cells was associated with a lack of
HIV-1 inhibition. These studies could potentially be gen-
eralized to other vector systems that express small RNA
inhibitors from this pol III promoter and should serve as
a warning to other investigators in the design of their gene
delivery vectors.
Results
Transduction of CEMx174 cells with the retroviral vectors
Previous studies have demonstrated effective inhibition of
HIV and SHIV-RT viral replication in aptamer-transduced
cells [11]. Towards evaluating the in vivo efficacy of the
HIV-1 RT-specific RNA aptamers, we sought to generate
high-titer stable Phoenix(amphotropic) [12] and Phoe-
nix(GaLV) [13] packaging cell lines. Therefore, we shut-
tled packaged the 4 MMP-GFP aptamer vectors (Figure 1a)
[11] by transient transfection through Phoenix(GaLV)
packaging cell lines and stable transduction of Phoe-
nix(amphotropic) packaging cell lines (Figure 1b).
Expression of GFP in the empty-, 70.15-, 70.8-, and 80.55-
transduced Phoenix(amphotropic) cells averaged 14%
before sorting (Table 1) and >95% after sorting. When
used for packaging of other MMP-GFP vectors, the titers of
the Phoenix(GaLV) cells were consistently less than 1 ×
105 IU/ml (data not shown). Therefore, Phoenix(GaLV)
cells were transduced with two serial exposures to super-
natant from the sorted Phoenix(amphotropic) cells.
Expression of GFP in the empty-, 70.15-, 70.8-, and 80.55-
transduced Phoenix(GaLV) cells averaged 65% before
sorting (Table 1) and >95% after sorting. Molecular anal-
ysis of the packaging cell lines after sorting (Table 1) indi-
cated that the Phoenix(amphotropic) cells had <1 copy
per cell (0.82, 0.33, 0.80, and 0.97 copies, respectively),
while the Phoenix(GaLV)-empty, -70.15, -70.8, and -
80.55 cells had on average 26 copies of integrated provi-
rus per cell (29, 26, 15, and 33 copies, respectively).
Table 1: Characterization of Phoenix (Amphotropic) and Phoenix (GaLV) packaging cell lines.
MMP Vector Phoenix (Amphotropic) Phoenix (GaLV)
Percent GFP1 Proviral copies2 Titer (TU/ml)3 Percent GFP1 Proviral copies2 Titer (TU/ml)3
Empty 7% 0.82 1.0 × 105 68% 29 2.6 × 105
70.15 18% 0.33 1.4 × 105 69% 26 2.5 × 105
70.8 17% 0.80 1.1 × 105 59% 15 2.1 × 105
80.55 14% 0.97 1.2 × 105 64% 33 2.5 × 105
1Initial percentage of GFP+ cells in each packaging cell line after transduction and prior to cell sorting.
2Molecular analysis of number of proviral copies of the GFP gene in each packaging cell line as determined by real-time PCR of genomic DNA.
3Calculated titer of the supernatant from each packaging cell line after limiting dilution and analysis of the expression of GFP in U2OS cells.AIDS Research and Therapy 2007, 4:24 http://www.aidsrestherapy.com/content/4/1/24
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To determine the number of infectious particles generated
by each cell line, supernatants from these producer cell
lines were used to transduce the human osteosarcoma cell
line U2OS, and GFP expression was evaluated in the
U2OS cells 48 hours post-transduction. As shown in Table
1, the titer of the amphotropic supernatants ranged from
1.1 to 1.4 × 105 infection units per ml (IU/ml), and the
titer of the GaLV-pseudotyped viruses ranged from 2.1 to
2.6 × 105 IU/ml. These stable high-titer producer cells
were used to generate both GaLV-pseudotyped and
amphotropic viral particles.
To evaluate the efficacy of these vectors to inhibit HIV-1
replication, we transduced CEMx174 cells, a CD4+ cell
line, with the GaLV-pseudotyped aptamer vectors (Figure
2a). The gene transfer efficiency of the empty, 70.15, 70.8,
and 80.55 aptamer into the CEMx174 cells was 42%,
45%, 52%, and 35%, respectively. Expression of GFP, as
Diagrams of the retroviral vectors and the shuttle-packaging scheme Figure 1
Diagrams of the retroviral vectors and the shuttle-packaging scheme. A) The MMP-based vector series contains GFP 
transcriptionally regulated by the MPSV LTR and the control or 3 different HIV-1 specific RT aptamers transcriptionally regu-
lated by the U6+1 promoter positioned in the antisense orientation. The forward and reverse arrows above GFP and the 3' 
UTR represent the PCR primers used to amplify the inhibitor cassette in transduced cells. B) Generation of high-titer producer 
cell lines by shuttle packaging. Vector plasmids were transiently transfected into Phoenix (GaLV) packaging cell line and super-
natant was used to transduce Phoenix (amphotropic) packaging cell lines. After selecting for Phoenix (amphotropic) cells 
expressing GFP, supernatants were collected for titering and to transduce Phoenix (GaLV) packaging cell lines with 2 expo-
sures. Supernatants from these Phoenix (GaLV) cells were collected for titration and to transduce the CD4+ cell line 
CEMx174.
A
B Plasmid
DNA
Phoenix 
(GaLV)
Phoenix 
(Ampho)
Supernatant 
Ampho
Lines Phoenix 
(GaLV)
Flow 
Sorted 
for GFP+
MMP-GFP
SD SA
MPSV MPSV GFP
70.8
80.55
empty
70.15AIDS Research and Therapy 2007, 4:24 http://www.aidsrestherapy.com/content/4/1/24
Page 4 of 14
(page number not for citation purposes)
Inhibition of HIV-1NL4-3 in aptamer transduced CEMx174 cells Figure 2
Inhibition of HIV-1NL4-3 in aptamer transduced CEMx174 cells. A) Transduction of the CD4+ cell line CEMx174. 
CEMx174 cells were transduced with each MMP-aptamer vector by spinoculation and overnight incubation with Phoenix 
(GaLV) supernatants. Cells were washed and expanded for 48 hours before analysis by flow cytometry. The dot plots indicate 
GFP expression versus side scatter characteristics for the empty vector (left plot), 70.15 vector (left center), 70.8 vector (right 
center), and 80.55 vector (right plot) before sorting. The percentage of GFP+ cells and the mean fluorescent intensity are indi-
cated in the upper right corner of the plot. B) Challenge of aptamer-transduced CEMx174 cells with HIV-1NL4-3. Aptamer-
transduced CEMx174 cells (empty, filled circle; 70.15, yellow square; 70.8, green diamond; 80.55, blue triangle) were sorted for 
expression of GFP, infected with HIV-1NL4-3 (MOI = 0.01 TCID50 per cell) and followed over 14 days for production of p24 Gag 
by ELISA.
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determined by flow cytometry, was strong with mean flu-
orescent intensities of 980, 1314, 1560, and 967 units.
After sorting for expression of GFP, aptamer-transduced
CEMx174 cells were challenged with HIV-1NL4-3 (MOI =
0.01 TCID50/cell, Figure 2b and MOI = 0.001 TCID50/cell,
data not shown) and assessed by ELISA for gag production
in the supernatant for two weeks. In contrast to previous
results that used a single round of packaging and pools of
individual CD4+  clones after limiting dilution plating
[11], we did not find any significant inhibition of viral
replication in the heterogeneous populations of aptamer-
transduced CEMx174 cells (Figure 2b).
Mechanism for the lack of inhibition in aptamer-
transduced CEMx174 cells
To explain the lack of inhibition we observed in our
aptamer-transduced CEMx174 cells, we hypothesized that
the retroviral vector was rearranged during shuttle packag-
ing and transduction. Since we had sorted the transduced
CEMx174 cells for expression of GFP, any structural rear-
rangements affecting the inhibitor cassette would need to
be downstream of the GFP sequences. Therefore, we
designed PCR primers to specifically amplify the aptamer
inhibitor cassette in the 3' UTR of MMP-GFP (Figure 1a).
PCR amplification of the four-retroviral plasmids gener-
ated the correct sized bands (Figure 3), excluding the pos-
sibility of a PCR artifact. However, PCR amplification of
genomic DNA from all four populations of aptamer-trans-
duced CEMx174 cells generated two bands on the agarose
gel (Figure 3) – one full-length product and another trun-
cated product approximately 100–150 bps smaller than
the full-length product.
Instability of the aptamer cassette in transduced CEMx174 cells Figure 3
Instability of the aptamer cassette in transduced CEMx174 cells. Genomic DNA from transduced cells and plasmid 
DNA from the different vectors were PCR amplified with a forward primer from GFP (3'GFP-for) and a reverse primer from 
the untranslated region of the vector (3' UTR-rev). PCR reactions were separated by gel electrophoresis and stained with 
ethidium bromide. The expected size of the MMP-70.15 amplicon is 654 bps; the expected size for the other bands varies 
depending on the length of the aptamer. The DNA ladders are either the 100 bp DNA ladder or the 1 kb DNA ladder from 
NEB.
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We initially examined whether the deletion was caused by
recombination of the short repeat elements in the flank-
ing ribozyme domains because of misalignment during
reverse transcription. To determine the nature of the dele-
tion, we gel purified and cloned the truncated product, the
full-length product, and the plasmid product for sequenc-
ing analysis. Individual clones were isolated and
sequenced. The consensus sequences of the clones from
the full-length PCR products and from the plasmid ampli-
con are identical to the predicted amplicon sequence (Fig-
ure 4a). In contrast, the sequence alignments from 20 of
21 clones from the truncated PCR product contain an
identical 139 bp deletion in the predicated amplicon
sequence (Figure 4a), while one clone contained the full-
Sequencing analysis of the truncated PCR product Figure 4
Sequencing analysis of the truncated PCR product. A) Multiple sequence alignment of the full-length and the truncated 
PCR products from 70.15-transduced CEMx174 cells with the PCR product from plasmid template. The sequence of the full-
length clones match the 654 bps predicted sequence from the plasmid template. The truncated product aligns with the pre-
dicted sequence except for a 139 bp deletion. The colored boxes indicate the transcription factor binding sequences: TATA 
box (red), the PSE (plum), and the sequences related to the octamer consensus (ATTTGCAT, blue), the protected SPH 
domain (light blue), while the grey boxes are non-functional octamer-related sequences [19, 20, 28]. The grey shading is the 
sequence of the HIV-1-specific RT aptamer 70.15 and the black box is the pol III termination signal. The bold sequences are the 
proposed splice donor and splice acceptor sequences. B) Schematic map of the predicted amplicon in forward orientation as 
described in Figure 1. The black arrows indicate the amplification primers. The boxes represent from left to right the 3' end of 
GFP, the Pol III termination sequence, a self-splicing ribozyme, the HIV-1-specific RT aptamer 70.15 (grey box), a self-splicing 
ribozyme, the human U6+1 promoter, and MMP 3' UTR sequences. The line represents linker sequences between the func-
tional sequences. The spotted ovals represent the TATA box (red) and PSE (plum) in proximal promoter; the non-function 
octamer sequences (grey), the Staf-binding domain (light blue) and the two octamer-related sequences (blue) in the distal pro-
moter all within the U6 promoter. A curved arrow represents the position and direction of the transcriptional start site. The 
black X represents the splicing deletion.
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B
Plasmid  1  GCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAAAGCGGCCGCTCGAAATTGTAAAAAGCGGACCG
Full-length 1  GCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAAAGCGGCCGCTCGAAATTGTAAAAAGCGGACCG
Truncated 1  GCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAAAGCGGCCGCTCGAAATTGTAAAAAGCGGACCG
Plasmid 91  AAGTCCGCTCTCGGCCGCTGCAGATCCGTTTCGTCCTCACGGACTCATCAGGACGGATCTAGATCCGTCGACGGATCCGGGCCCGTTTTC
Full-length  91  AAGTCCGCTCTCGGCCGCTGCAGATCCGTTTCGTCCTCACGGACTCATCAGGACGGATCTAGATCCGTCGACGGATCCGGGCCCGTTTTC
Truncated  91  AAGTCCGCTCTCGGCCGCTGCAGATCCGTTTCGTCCTCACGGACTCATCAGGACGGATCTAGATCCGTCGACGGATCCGGGCCCGTTTTC
Plasmid 181  CAGAGTTTTCCCCCTTATCTCCTGGGTTCGTAGGGAATTCGAGCTCGAGCTGACGGTACCGGGTACCGTTTCGTCCTCACGGACTCATCA
Full-length 181  CAGAGTTTTCCCCCTTATCTCCTGGGTTCGTAGGGAATTCGAGCTCGAGCTGACGGTACCGGGTACCGTTTCGTCCTCACGGACTCATCA
Truncated  162  CAGAGTTTTCCCCCTTATCTCCTGGGTTCGTAGGGAATTCGAGCTCGAGCTGACGGTACCGGGTACCGTTTCGTCCTCACGGACTCATCA
Plasmid 271  GAGCTCGAGCTAGACCGGTCGACGGTGTTTCGTCCTTTCCACAAGATATATAAAGCCAAGAAATCGAAATACTTTCAAGTTACGGTAAGC
Full-length 271  GAGCTCGAGCTAGACCGGTCGACGGTGTTTCGTCCTTTCCACAAGATATATAAAGCCAAGAAATCGAAATACTTTCAAGTTACGGTAAGC
Truncated  271  GAGCTCGAGCTAGACCGGTCGACGGTGTTTCGTCCTTTCCACAAGATATATAAAGCCAAGAAATCGAAATACTTTCAAGTTACG------
Plasmid 361  ATATGATAGTCCATTTTAAAACATAATTTTAAAACTGCAAACTACCCAAGAAATTATTACTTTCTACGTCACGTATTTTGTACTAATATC
Full-length 361  ATATGATAGTCCATTTTAAAACATAATTTTAAAACTGCAAACTACCCAAGAAATTATTACTTTCTACGTCACGTATTTTGTACTAATATC
Truncated  355  ------------------------------------------------------------------------------------------
Plasmid 451  TTTGTGTTTACAGTCAAATTAATTCTAATTATCTCTCTAACAGCCTTGTATCGTATATGCAAATATGAAGGAATCATGGGAAATAGGCCC
Full-length 451  TTTGTGTTTACAGTCAAATTAATTCTAATTATCTCTCTAACAGCCTTGTATCGTATATGCAAATATGAAGGAATCATGGGAAATAGGCCC
Truncated  355  -------------------------------------------CCTTGTATCGTATATGCAAATATGAAGGAATCATGGGAAATAGGCCC
Plasmid 541  TCTTCCTGCCCGACCTTGGATCCCCGGGTACCGAGATCCGGATTAGTCCAATTTGTTAAAGACAGGATATCAGTGGTCCAGGCTCTAGTT
Full-length 541  TCTTCCTGCCCGACCTTGGATCCCCGGGTACCGAGATCCGGATTAGTCCAATTTGTTAAAGACAGGATATCAGTGGTCCAGGCTCTAGTT
Truncated  402  TCTTCCTGCCCGACCTTGGATCCCCGGGTACCGAGATCCGGATTAGTCCAATTTGTTAAAGACAGGATATCAGTGGTCCAGGCTCTAGTT
Plasmid 631  TTGACTCAACAATATCACCAGCT
Full-length 631  TTGACTCAACAATATCACCAGCT
Truncated  492  TTGACTCAACAATATCACCAGCT
GFP Stop Rz 70.15 Rz U6 Promoter MMP 3’ UTR
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length sequence. When the deletion was compared to the
predicted amplicon sequence, the deletion was mapped
from bases -62 to -200 (relative to the transcriptional start
site) in the middle of the U6 promoter (Figure 4a). These
data demonstrate that the deletion in the inhibitor cas-
sette did not occur in the sequences between the repeat
elements in the self-splicing ribozymes but occurred in
the promoter region during post-transcriptional process-
ing of the mRNA, potentially from splicing of retroviral
genomic mRNA.
To address whether inadvertent RNA splicing of the inhib-
itor cassette in the antisense orientation was responsible
for generating the deletion, we compared the antisense
sequence in the deletion of the U6 promoter to consensus
splicing signals. As shown in Figure 5a, the GU and AG at
the ends of most introns, along with the internal stretch of
pyrimidines and other frequently occurring nucleotides,
define the consensus sequences for splice donor and
splice acceptor sites (reviewed in [14-16]). In most exons,
the unspliced sequence is (A/C)AG at the donor site and
G at the acceptor sites (Figure 5a) [14-16]. However, the
Comparison of the antisense U6 promoter with splicing consensus sequences Figure 5
Comparison of the antisense U6 promoter with splicing consensus sequences. A) Top row: the consensus splice 
donor and splice acceptor sequences with the intron sequences (red bold with a red bold line above) and the exon sequences 
(normal font with a thin line above). The necessity for the internal pyrmidine stretch is represented by the 10Y. The nucle-
otide-usage percentage at each position is noted as a subscript. M equals adenosine or cytosine, Y equals pyrimidines and R 
equals purine. Bottom row: the antisense U6 promoter sequences surrounding the 139 bp deletion with the sequences that 
remain (in normal font with a thin line below) and the sequences that were deleted (in red bold with a red bold line below). B) 
Top row: The consensus sequences for the internal branch point are represented with the nucleotide-usage percentage noted 
as a subscript. The distance of the invariant adenosine to the splice acceptor site is noted in parentheses. Potential branch sites: 
5 potential branch sites in the antisense U6 promoter are indicated. Divergent sequences are shown in normal font and con-
served sequences are shown in bold. All sequences are intronic and shown in red. The distances to the end of the deletion are 
noted in parentheses.
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sequences at the intron/exon junction are not sufficient to
signal the presence of an intron. The branch point is
another required sequence usually located 20 – 50 bases
upstream of the acceptor [14-16]. The consensus sequence
of the branch point is "CU(Pu)A(Py)", where adenosine is
absolutely required for splicing (Figure 5b) [14-16]. Addi-
tional positive and negative recognition elements are also
necessary [14-16]. Interestingly, the junctions of the
deleted sequences in the U6 promoter contain the requi-
site GU and AG sequences and show very strong similari-
ties to the splice donor splice acceptor consensus
sequences with an internal pyrimidine stretch (Figure 5a).
Because the branch point consensus sequences are more
flexible, the antisense U6 promoter has potential branch
sites 3, 15, 21, 25, and 46 bps upstream of the splice
acceptor site (Figure 5b). All these sites contain the requi-
site adenosine. The few divergent sequences in these
potential branch points are shown in normal font.
To determine whether the truncated aptamer cassette orig-
inated during post-transcriptional splicing of the mRNA
or after later steps in the retroviral life cycle, we isolated
total RNA from the Phoenix (amphotropic) packaging cell
lines after transfection with each of the aptamer vectors.
Under these conditions, the inhibitor cassette will have
been transcribed and the RNA processed, but will not have
progressed to reverse transcription and/or integration. The
total RNA from the packaging cell line was amplified by
RT-PCR with or without reverse transcriptase using the
same primer combination (Figure 1a) as was used previ-
ously to amplify the aptamer in Figure 3. In all four trans-
fected Phoenix (amphotropic) populations, both the full-
length and the truncated product were detected (Figure 6),
while amplification of the MMP-70.15 plasmid generated
only the full-length product and amplification of the RNA
samples without RT were negative (Figure 6). The ratio of
full-length to truncated product during one round of tran-
scription and mRNA processing favors the full-length
product (Figure 6). Because the RT-PCR reaction was not
Deletion of aptamer cassette in RNA transcripts from the Phoenix(amphotropic) packaging cell lines Figure 6
Deletion of aptamer cassette in RNA transcripts from the Phoenix(amphotropic) packaging cell lines. The 
Phoenix (amphotropic) packaging cell lines were transfected with the different aptamer vectors. Total RNA was isolated and 
subjected to amplification by RT-PCR with (+RT) or without (-RT) reverse transcriptase using the 3'GFP-for and 3' UTR-rev 
primers. Amplification of the MMP 70.15 plasmid was included as control. The DNA ladder is the 100 bp DNA ladder from 
Invitrogen.
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designed or evaluated for quantitative analysis, the effi-
ciency of RNA processing cannot be determined. These
results demonstrate that the deletion in the U6 promoter
when transduced in the antisense orientation within a ret-
roviral vector is caused by splicing of the retroviral
genomic RNA at cryptic splice donor/splice acceptor
sequences.
Comparisons of the deletion with the functional domains
of the U6 promoter revealed that the deletion removes 5
of 19 bps in the proximal sequence element (PSE) and
two non-functional Oct-1 binding domains in the distal
enhancer, but not the functional Oct-1 and SPH elements
in the distal enhancer (Figure 4). The 139 bp deletion also
changes the spacing between the enhancer element and
the PSE within the U6 promoter to only 13 bps (Figure 4).
Previous studies have shown that the promoter is tran-
scriptionally active with limited distance between the PSE
and the upstream enhancer elements [17]. To determine
whether the deletion had an effect on the transcriptional
activity of the U6 promoter, we used the pCRII plasmids
containing full-length and truncated U6 promoter-70.15
amplicons to transiently transfect 239T cells and quanti-
fied expression of the 70.15 aptamer by Northern blot
(Figure 7). Endogenous expression of the U6 snRNA gene
was used to normalize samples (Figure 7). The mutation
Northern blot of wildtype and mutant U6 promoter activity Figure 7
Northern blot of wildtype and mutant U6 promoter activity. Plasmid DNA with the wildtype (wt) and mutant U6 pro-
moters transcriptionally regulating the aptamer 70.15 were transfected into 293T cells. After 48 hours, total RNA was isolated, 
separated by electrophoresis, blotted and probed for expression of the aptamer 70.15 and of the U6 snRNA (endogenous con-
trol). Shown are 3 replicates for the aptamer and the U6 snRNA. The intensity of each band (x104 units) was quantified with 
the STORM 820 phosphorimager and is shown below the image. A relative ratio of the aptamer 70.15 signal to the endogenous 
U6 snRNA expression is shown. The fold decrease of mutant U6 promoter activity and Wt U6 promoter activity in regulating 
transcription of the aptamer 70.15 is indicated below the line for each replicate. The reduction in expression of the mutant U6 
promoter was 0.50 ± 0.12 fold (mean ± standard deviation [SD]).
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in the U6 promoter consistently reduced expression of the
70.15 aptamer compared to the wildtype U6 promoter
(0.50 ± 0.12, mean ± SD) but did not completely elimi-
nate expression (Figure 7). Thus, deletion of 139 bps
within the U6 promoter, either through loss of a portion
of the PSE and/or through alterations in the spatial
arrangement of transcription factors, lowered U6 pro-
moter activity.
Discussion
Towards a stem cell gene therapy strategy for AIDS, we
studied transduction of three different HIV-1-specific RNA
aptamers and one control aptamer transcriptionally regu-
lated by the U6 promoter in the antisense orientation
within a retroviral vector. After shuttle packaging and
transduction of CD4+ cell lines, these vectors were no
longer able to inhibit HIV-1 replication. Instead, we
found deletions within the U6 promoter in all 4 vectors
after retroviral mediated gene transfer and consensus
splicing signals in the U6 promoter in the reverse orienta-
tion.
The classical splicing consensus sequences and basal splic-
ing machinery have been described for many years [14-
16]. The basal splicing machinery recognizes the classical
splicing sequences and catalyzes the reaction removing
the intron and joining the exons together. At the ends of
the exon and introns are the well-described splice donor-
splice acceptor sequences (see Figure 5) and within the
intron is an internal branch point with a requisite adeno-
sine that is necessary for the intramolecular lariat bond.
Additionally, auxiliary elements within exon or introns
are commonly required for efficient constitutive or alter-
native splicing. Finding similar classical splicing consen-
sus sequences surrounding the deletion in the U6
promoter suggests that the splicing of this cryptic intron
during transcription of the retroviral genomic RNA in the
packaging cell lines caused the deletion.
Although the antisense U6 promoter closely matches the
consensus splice donor/splice acceptor sites and has 5
potential internal branch sites, splicing of the antisense
U6 promoter is inefficient. In the RT-PCR analysis of
aptamer expression in cells transfected with the four dif-
ferent aptamer vectors, we observed only a small fraction
of the shorter deleted product after only a single cycle of
transcription and potential RNA splicing. In the genomic
DNA from transduced CEMx174 cells after the retroviral
vector was shuttle packaged, amplification of both the
full-length and truncated products was observed, even
after the vector underwent multiple rounds of viral repli-
cation (i.e., transcription, reverse transcription and inte-
gration). It appears that the mismatches in the splicing
consensus sequences or that other auxiliary splicing sig-
nals may be necessary for efficient splicing of the antisense
U6 promoter. Although splicing is detectable, the fre-
quency is low, and this provides some optimism for vec-
tors that have been produced with the U6 promoter in the
antisense direction. However, our finding a similar dele-
tion in four separate MMP-aptamer transduced popula-
tions reinforces that this splicing-induced deletion occurs
reproducibly and that multiple cycles of retroviral packag-
ing and transduction would only serve to increase the frac-
tion of truncated product.
The molecular mechanism of transcriptional activation
with U6 promoters has been thoroughly studied [18].
RNA polymerase (pol) II promoters and pol III promoters
for snRNA genes are very similar, even using common
binding factors (reviewed in [18]). The U6 pol III pro-
moter contains 3 protein-binding domains: the proximal
sequence element (PSE) and the TATA box are approxi-
mately 50 and 25 bps upstream of the transcriptional ini-
tiation site and the distal enhancer element is
approximately 200 bps upstream of the transcriptional
initiation site. For basal transcription, the PSE binds the
snRNA activating protein complex (SNAPc) of five pro-
teins (as they do in the pol II PSEs), while the TATA box
binds to the initiation complex TFIIIB (reviewed in [18]).
TFIIIB, like the TFIIB for pol II promoters, facilitates inter-
actions with the RNA polymerase and is required for all
pol III promoters, even the separated tRNA-type promot-
ers. For the human U6 promoter, TFIIIB consists of the
TATA box binding protein (TBP), TFIIIB50 and TFIIIB90.
Meanwhile, the distal enhancer element binds multiple
factors (Oct-1, ZNF143 and ZNF76) that stimulate the for-
mation of preinitiation complexes, with some proteins
activating both pol II and pol III snRNA gene transcrip-
tion. Correct nucleosome positioning between the
enhancer and PSE during chromatin assembly also brings
into close proximity the two binding domains and allows
for cooperative interactions with the Oct-1 and SNAPc. A
stable initiation complex recruits either RNA pol II or III
and results in snRNA transcription.
The effects of the splicing deletion we observed in the
aptamer vectors on cooperative binding and transcrip-
tional activity may be complex because the 139 bps splic-
ing deletion mutates potential transcription factor
binding sites and changes the alignment of the remaining
sites. In the proximal promoter, five of 19 bps from the
PSE are deleted, which may limit SNAPc binding [18]. In
the distal U6 enhancer, two of the 4 total octamer consen-
sus sequences (ATTTGCAT [19]) are also deleted. We do
not believe loss of these two non-functional [19] domains
contributes to the decreased promoter activity, since the
deleted U6 promoter still contains the two functional
octamer binding sequences: 1) the SPH motif, which
binds to ZNF76 and ZNF143 [20], and 2) the Oct-1 bind-
ing sites, which is involved in the cooperative binding ofAIDS Research and Therapy 2007, 4:24 http://www.aidsrestherapy.com/content/4/1/24
Page 11 of 14
(page number not for citation purposes)
SNAPc to the U6 promoter that leads to increase recruit-
ment of pol III and transcriptional initiation [21]. Addi-
tionally, the splicing deletion may affect transcriptional
activity because correct nucleosome positioning in the U6
promoter allows for the juxtaposed positioning of the dis-
tal enhancer with the proximal PSE necessary for their
cooperative interactions [22]. Thus, removing 134 bps
from the U6 promoter will change the spatial alignment
of the transcription factors with only 13 bps remain
between the two DNA binding domains. In gel shift
assays, cooperative binding of Oct-1 and SNAPc still
occurs in recombinant promoters with only 18, 23, and
27 bps separation [17]. Our Northern blots demonstrate
that the deletion in the U6 promoter decreased, but did
not completely eliminate, transcriptional activity. Some
limited interaction must be possible between the SNAPc
on the PSE and with Oct-1 in the enhancer.
Many factors in the configuration of retroviral vectors play
a role in gene expression and activity. We initiated these
studies when we observed a lack of inhibition of HIV-1
replication in cells that had been transduced with HIV-
specific aptamer vectors generated using a shuttle packag-
ing protocol. Interestingly, we found the splicing deletion
in the U6 promoter that reduced transcriptional activity.
However, not all transduced cells contained the splicing
deletion, indicating that the transduced populations con-
tained a mixture of wildtype and deleted promoters. In
our earlier work [11], we showed inhibition of HIV-1 with
a gamma-retroviral vector expressing GFP and containing
the U6-aptamer cassettes in the reverse orientation. These
previous studies used a single round of packaging and
pools of individual clones after limiting dilution plating
for expression and challenge studies. In the present stud-
ies, we shuttle packaged the same vectors between ampho-
tropic- and GaLV-pseudotyped Phoenix packaging cell
lines to generate higher titer clones for subsequent in vivo
experiments. In the process, amplification of the vector
during shuttle packaging also allowed for several cycles of
RNA processing and the enrichment of aptamer cassettes
with the splicing deletion in transduced cells. Addition-
ally, the present studies used bulk populations of trans-
duced cells (sorted for GFP expression) rather than pools
of clones. The position-dependent effects of the integra-
tion site in the T cell clones may have resulted in higher
levels of aptamer expression than we observed in bulk
populations of transduced cells with heterogeneous inte-
gration sites. Consequentially, abundant aptamer expres-
sion was detected previously in the T cell clones by RNase
protection assay [11], while aptamer expression in the
bulk transduced cells analyzed in this report was not
detected by northern blot and RNase protection assay
(data not shown). While the splicing deletion we
observed in the U6 promoter reduced transcriptional
activity, other factors in the vector design must also con-
tribute to the overall lack of aptamer expression and viral
inhibition that we observed in the transduced cells. We
are currently examining other pol III promoters in the
reverse and forward orientations to determine which vec-
tors will permit stable gene transfer, the highest level of
expression and the strongest inhibition. Interestingly,
many gene transfer studies with the U6 promoter have
used the complete U6 promoter, even though a minimal
promoter with only the distal and proximal elements is
active. Recently, the U6 promoter has also been used in
lentiviral-based retroviral vectors to regulate siRNA inhib-
itors of either HIV-1 or of host cellular genes [4,23,24].
These SIN-type lentiviral vectors, with a deletion in the 3'
LTR to inactivate the HIV-1 promoter after reverse tran-
scription and integration, have the U6 promoter-inhibitor
cassette in the forward direction, and thus would not be
subject to the deletion via the cryptic splice site described
in this report.
Conclusion
We found deletions of the U6 promoter that matched
closely with the classical splicing consensus sequences
when transferred in a retroviral vector in the antisense ori-
entation. The deletion reduced the transcriptional activity,
and the lack of detectable aptamer expression in bulk
transduced cells was associated with a lack of HIV-1 inhi-
bition. These studies could potentially be generalized to
other vector systems that express small RNA inhibitors
from this polymerase III promoter and should serve as a
warning to other investigators in the design of their inhib-
itor vectors.
Methods
Cell culture and transduction conditions
The CD4+ cell line CEMx174 was cultured in RPMI-1640
(Sigma, St. Louis, MO) plus 20% fetal bovine serum (FBS,
HyClone, Logan, UT), 10 mM HEPES (Cellgro/Mediatech,
Fisher Scientific, Federal Way, WA), 50 U/ml penicillin
and 50 µg/ml streptomycin (Cellgro/Mediatech), 2 mM L-
glutamine (Cellgro/Mediatech), (R20 medium) at 37°C
with 5% CO2. CEMx174 cells were exposed to viral super-
natants plus 8 µg/ml polybrene (Sigma) with a 20 min-
utes spin at 200 rpm and then overnight culture. After 24
hours, the cells were washed and expanded in R20 media.
Phoenix (amphotropic) [12], Phoenix (GaLV) packaging
cell lines [13] (both based on 293T cells), and U2OS cells
were cultured in DMEM plus 10% FBS, 10 mM HEPES, 50
U/ml penicillin and 50 µg/ml streptomycin, 2 mM L-
glutamine (D10 medium) at 37°C with 5% CO2.
Generation and evaluation of high-titer producer cell lines
The MMP vectors were previously described [11]. Plasmid
DNAs of the four retroviral vectors was transfected into
the Phoenix (GaLV) packaging cell line by calcium phos-
phate co-precipitation and washed after 24 hours. After 48AIDS Research and Therapy 2007, 4:24 http://www.aidsrestherapy.com/content/4/1/24
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hours, culture supernatant was collected, passed through
a 0.45-micron filter and used to transduce the Phoenix
(amphotropic) packaging cell line. Aptamer-transduced
Phoenix (amphotropic) cells were sorted for expression of
GFP using a Becton Dickinson FACS Vantage. These heter-
ogeneous populations of cells were used to generate
supernatant for titering and for transducing Phoenix
(GaLV) packaging cell lines. Aptamer-transduced Phoenix
(GaLV) cells were sorted for expression of GFP. These het-
erogeneous populations of cells were used to generate
supernatant for titering and for transducing CEMx174
cells. Dilutions of viral stocks were used to transduce
U2OS cells and the percent GFP positive cells determined
by flow cytometry. Stock titers ranged from 1.0 to 2.6 ×
105 transduction units (TU)/ml (Table 1).
Viral inhibition assays
The HIV-1 strain NL4-3 was kindly provided by Ronald C.
Desrosiers (NEPRC, HMS). Viral stocks were generated by
infection of CEMx174 cells and harvesting cell-free super-
natants on day 8–12 after infection. Virus stocks were ana-
lyzed for Gag production by ELISA (HIV p24, Coulter
HIV-1 Core Antigen Assay; Coulter International Corp.,
Miami, FL) per the manufacturer's instructions and/or
titered for TCID50 values by limiting dilution assay as pre-
viously described [25].
To challenge aptamer-transduced and control CEMx174
cells for viral replication, transduced cells were resus-
pended for 4 hours in HIV-1 at MOIs of 0.001 to 0.01
TCID50/cell, before being washed and cultured in 15 ml
R20. Production of p24 Gag in the supernatant was
assessed by ELISA (Beckman Coulter, Fullerton CA) in
cell-free supernatants to quantify viral replication.
Molecular analysis
Genomic DNA was isolated from transduced cells using
the QIAamp Blood Mini Kits (Qiagen, Valencia, CA). The
inhibitor sequence from each transduced population was
amplified using the forward 3'GFP (5'-GCT GGA GTT
CGT GAC CGC-3') and the reverse MMP 3' UTR (5'-AGC
TGG TGA TAT TGT TGA GTC AAA AC-3') primers as
shown in Figure 1. Reaction mixtures containing 500 ng
genomic DNA, 200 nM of each primer, 0.2 mM dNTPs in
50 µl of 1× PCR buffer (Invitrogen Corp., Carlsbad, Cali-
fornia) were amplified with annealing temperature of
56°C, elongation temperature of 72°C, and denaturation
temperature of 94°C for 35 cycles, using Platinum Taq
DNA polymerase (Invitrogen). Samples were separated by
agarose electrophoresis and stained with ethidium bro-
mide. The image was captured using the Alpha Innoteck
Corp. Imager program version 3.24 (Alpha Innoteck
Corp., San Leandro, CA).
The PCR product for each band was gel purified (Qiagen)
and cloned into pCR®II-blunt-TOPO® using Zero Blunt
TOPO PCR Cloning Kit (Invitrogen). At least 18 individ-
ual clones for each PCR product were isolated and
sequenced on a CEQ™8000 Genetic Analysis System
(Beckman Coulter, Fullerton CA) using CEQ™DTCS-
Quick Start Kit (Beckman Coulter) according to the man-
ufacturer's instructions.
Sequence data and chromatogram data from the individ-
ual clones were aligned using ContigExpress in the Vector
NTI Suite (Invitrogen). Consensus sequences were gener-
ated and compared to the predicted amplicon sequence
using BEAUTY (BLAST Enhanced Alignment Utility) [26],
an enhanced version of the Basic Local Alignment Search
Tool (BLAST) from the National Center for Biotechnology
Information (NCBI), on the Baylor College of Medicine
website [29]. Multiple sequence alignments were gener-
ated using the Multiple Sequence Alignment Program [27]
at the Baylor College of Medicine website.
The Phoenix (amphotropic) packaging cell line was trans-
fected with the different retroviral plasmids containing
the HIV-1-specific RT aptamers using lipofectamine 2000
(Invitrogen) 48 hours prior to total RNA isolation with
using Qiagen RNA easy (Qiagen). The inhibitor sequence
from each transfected population was amplified using the
same forward 3'GFP and the reverse MMP 3' UTR primers.
The reaction mixtures contained 1 µg of total RNA and
200 nM of each primer, 0.2 mM dNTPs, 1.6 mM MgSO4,
in 50 µl of 1× One-step Master mix (Invitrogen). The sam-
ples was reverse transcribed at 56°C for 30 mins with
(RT+) or without (RT-) 25 units of the reverse transcriptase
Superscript III (Invitrogen), and amplified with annealing
temperature of 56°C, elongation temperature of 72°C,
and denaturation temperature of 94°C for 40 cycles, using
Platinum Taq DNA polymerase (Invitrogen). Samples
were separated on 1.2% agarose gel and stained with
ethidium bromide. The image was captured using the
Alpha Innoteck Corp. Imager program version 3.24
(Alpha Innoteck Corp., San Leandro, CA).
Northern Blot
The pCRII TOPO plasmids corresponding to the wildtype
(wt) and splicing mutant (mut) U6 promoter-70.15
aptamer expression cassettes were transiently transfected
into 293T cells with lipofectamine 2000 (Invitrogen) per
the manufacturer's instructions. As a control for the trans-
fection efficiency, the constitutively active SEAP expres-
sion cassette was also transfected and soluble SEAP
activity quantified. Two days after transfection, total RNA
was isolated from the aptamer-expressing 293T cells by
Trizol (Invitrogen). The amount of RNA in each sample
was calculated from the optical density at 260 nm
(OD260). RNA samples were subjected to electrophoresisAIDS Research and Therapy 2007, 4:24 http://www.aidsrestherapy.com/content/4/1/24
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in 8% denaturing polyacrylamide gel, transferred to a
nylon membrane (Hybond N+, Amersham Pharmacia
Biotech) and hybridized with a 32P-labeled RNA aptamer,
tRNALys3 or U6 snRNA probe. After stringent washing of
the membrane, images were captured and the bands were
quantified by the phosphorimager (STORM 820; Molecu-
lar Dynamics).
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